[Clinicopathologic analysis of 57 cases of primary pulmonary mucinous adenocarcinoma].
OBJECTIVE
To summarize the clinicopathological characteristics and prognostic factors of primary pulmonary mucinous adenocarcinoma (PPMA).


METHODS
The clinicopathological manifestations and radiological appearances of 57 PPMA patients surgically treated and pathologically proved between Jan. 2001 and Dec. 2006 were retrospectively analyzed. The cumulated survival rate was calculated by life table method.


RESULTS
There were no specific clinical manifestations in PPMA patients, while the tumors were radiologically pleomorphologic. Of these 57 patients, 5 were in stage Ia, 20 in stage Ib, 1 in stage IIb, 11 in stage IIIa, 6 in stage IIIb and 14 in stage IV. The cumulated 1-, 3- and 5-year survivals of those with complete resection were 88.0%, 55.0% and 55.0%, respectively.


CONCLUSIONS
The final correct diagnosis of primary pulmonary mucinous adenocarcinoma should be made by pathology. Though the treatment is not different, the prognosis of the patients with primary pulmonary mucinous adenocarcinoma is better than that of those with adenocarcinoma.
Zhang
Jie
J
Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China.
Chen
Chang
C
Zheng
Hui
H
Chen
Gang
G
D002288:Adenocarcinoma, Mucinous / Q000473:pathology* / Q000628:therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000627:therapeutic use; D009367:Neoplasm Staging; D011013:Pneumonectomy; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D015996:Survival Rate; D014747:Vinblastine / Q000627:therapeutic use
D008937:Mitomycins; D014747:Vinblastine; D002945:Cisplatin